Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Quinazoline Based HDAC Dual Inhibitors as Potential Anti-Cancer Agents
Jyothi Dhuguru, Ola Ghoneim
Molecules (2022) Vol. 27, Iss. 7, pp. 2294-2294
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
Ali Doostmohammadi, Hossein Jooya, Kimia Ghorbanian, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 20
Single Inhibitors versus Dual Inhibitors: Role of HDAC in Cancer
Rubi Roy, Tasnim Ria, Debapriya RoyMahapatra, et al.
ACS Omega (2023) Vol. 8, Iss. 19, pp. 16532-16544
Open Access | Times Cited: 26
Synthesis, investigation of the crystal structure, DFT and in silico medicinal potential of nicotinonitrile substituted quinazolindione as potential anticancer scaffold
Sabir Ali Siddique, Shaaban K. Mohamed, Muhammad Sarfraz, et al.
Molecular Physics (2025)
Closed Access
The literature of heterocyclic chemistry, part XXII, 2022
Галина А. Газиева, Yu. B. Evdokimenkova, N. O. Soboleva
Advances in heterocyclic chemistry (2025)
Closed Access
Identification and exploration of quinazoline-1,2,3-triazole inhibitors targeting EGFR in lung cancer
Sunil Kumar, Sounok Sengupta, Iqra Ali, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 41, Iss. 21, pp. 11353-11372
Closed Access | Times Cited: 14
Dual inhibitors of HDAC and other epigenetic regulators: A novel strategy for cancer treatment
Ekta Shirbhate, Vaibhav Singh, Varsha Jahoriya, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115938-115938
Closed Access | Times Cited: 13
Double‐strand DNA break repair: molecular mechanisms and therapeutic targets
Jinpeng Tan, Xingyao Sun, Hongling Zhao, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 12
Heterocycles‐Containing HDAC Inhibitors Active in Cancer: An Overview of the Last Fifteen Years
A. Russo Raucci, Carola Castiello, Antonello Mai, et al.
ChemMedChem (2024)
Open Access | Times Cited: 3
Recent advances on quinoxalines as target‐oriented chemotherapeutic anticancer agents through apoptosis
Mohamed S. Nafie, S. Kahwash, Magdy M. Youssef, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 9
Closed Access | Times Cited: 3
G9a in Cancer: Mechanisms, Therapeutic Advancements, and Clinical Implications
Yuchao Ni, Mingchen Shi, Liangliang Liu, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2175-2175
Open Access | Times Cited: 3
6-Bromo quinazoline derivatives as cytotoxic agents: design, synthesis, molecular docking and MD simulation
Leila Emami, Maryam Hassani, Pegah Mardaneh, et al.
BMC Chemistry (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 3
An insight into therapeutic efficacy of heterocycles as histone‐modifying enzyme inhibitors that targets cancer epigenetic pathways
N. Jeelan Basha, S. M. Basavarajaiah
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 5, pp. 682-698
Closed Access | Times Cited: 20
Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide
Udayan Bhattacharya, Mohammad Kamran, Maroua Manai, et al.
Cancers (2023) Vol. 15, Iss. 2, pp. 332-332
Open Access | Times Cited: 8
Introducing Fe3O4@SiO2@KCC-1@MPTMS@CuII catalytic applications for the green one-pot syntheses of 2-aryl(or heteroaryl)-2,3-dihydroquinazolin-4(1H)-ones and 9-aryl-3,3,6,6-tetramethyl-3,4,5,6,7,9-hexahydro-1H-xanthene-1,8(2H)-diones
Morteza Hasanpour Galehban, Behzad Zeynizadeh, Hossein Mousavi
Journal of Molecular Structure (2022) Vol. 1271, pp. 134017-134017
Closed Access | Times Cited: 14
Advances in long non-coding RNA regulating drug resistance of cancer
Ying Zhang, Wenjing Sun, Jing Bai, et al.
Gene (2023) Vol. 887, pp. 147726-147726
Open Access | Times Cited: 6
Recent drug design strategies and identification of key heterocyclic scaffolds for promising anticancer targets
Alia Mushtaq, Peng Wu, Muhammad Moazzam Naseer
Pharmacology & Therapeutics (2023) Vol. 254, pp. 108579-108579
Closed Access | Times Cited: 6
Transition metal(ii) complexes of halogenated derivatives of (E)-4-(2-(pyridin-2-ylmethylene)hydrazinyl)quinazoline: structure, antioxidant activity, DNA-binding DNA photocleavage, interaction with albumin andin silicostudies
Chrisoula Kakoulidou, Christos T. Chasapis, Antonios G. Hatzidimitriou, et al.
Dalton Transactions (2022) Vol. 51, Iss. 43, pp. 16688-16705
Open Access | Times Cited: 9
Anticancer Biological Profile of Some Heterocylic Moieties-Thiadiazole, Benzimidazole, Quinazoline, and Pyrimidine
Parin Salim Sidat, Tasneem Mohamadbin Kasim Jaber, Shwetang Ramesh Vekariya, et al.
Pharmacophore (2022) Vol. 13, Iss. 4, pp. 59-71
Open Access | Times Cited: 9
Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition
Mei Li, Daoping Wang, Qing Li, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6851-6851
Open Access | Times Cited: 4
Synthesis and biological evaluation of novel N-benzyltriazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors
Sun Ju Kong, Gibeom Nam, Pulla Reddy Boggu, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 79, pp. 117154-117154
Closed Access | Times Cited: 3
Synthesis, Characterization and Molecular Docking Study of Novel 1,4-Dihydropyridine Derivatives as Antimicrobial and Anticancer Agents
Fereshteh Gandomi, Karim Akbari Dilmaghani, Bakhshali Massoumi, et al.
Russian Journal of Bioorganic Chemistry (2023) Vol. 49, Iss. 5, pp. 1089-1099
Closed Access | Times Cited: 3
Synthesis, in silico and in vitro antimicrobial efficacy of substituted arylidene-based quinazolin-4(3H)-one motifs
Gbolahan O. Oduselu, Damilola V. Aderohunmu, Olayinka O. Ajani, et al.
Frontiers in Chemistry (2023) Vol. 11
Open Access | Times Cited: 3
Identification of 2,4-Diaminoquinazoline Derivative as a Potential Small-Molecule Inhibitor against Chikungunya and Ross River Viruses
Amrita Saha, Badri Narayan Acharya, Manmohan Parida, et al.
Viruses (2023) Vol. 15, Iss. 11, pp. 2194-2194
Open Access | Times Cited: 2
The Mystery of EVP4593: Perspectives of the Quinazoline-Derived Compound in the Treatment of Huntington’s Disease and Other Human Pathologies
Dmitriy A. Grekhnev, Anna A. Kruchinina, Vladimir Vigont, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15724-15724
Open Access | Times Cited: 4
Hybrid arginine-modified phospholipid nanotherapeutics based on multitarget quinoxalin-2-ones for cancer-cells delivery
Tatiana N. Pashirova, Lilia V. Mustakimova, Irek R. Nizameev, et al.
Journal of Molecular Liquids (2024) Vol. 407, pp. 125149-125149
Closed Access
Page 1 - Next Page

Scroll to top